 |
| Research article summary (published 30 Jan 2003): |
|
Free Full Text! See links below |
A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men.
Full Abstract
This report describes a Phase II, multicenter, contraceptive efficacy clinical trial using monthly injections of testosterone undecanoate (TU) alone at a dose of 500 mg in healthy Chinese men. Three hundred eight healthy men were recruited in six centers distributed throughout China. Volunteers underwent a control period with no treatment, then a 12-month treatment period including a 6-month suppression phase followed by a 6-month efficacy phase and a 12-month recovery period. During the suppression phase, an initial loading dose of 1000 mg TU, followed by 500 TU at monthly intervals were given until azoospermia or severe oligozoospermia was achieved, up to a maximum of six injections. During the efficacy phase, 500 mg TU were administered at monthly intervals for 6 months. Nine of 308 men did not achieve azoospermia or severe oligozoospermia (<3 x 10(6)/ml) within the 6-month suppression phase. This gave a methodological failure rate of 2.9/100 couple years (95% confidence interval of 1.0-4.8/100 couple years). Two hundred ninety-six men entered the efficacy phase. The continuation rate during the efficacy phase was 95/100 couple years. There were no pregnancies caused by men who achieved azoospermia or severe oligozoospermia. Reappearance of sperm occurred in six men during the efficacy phase, and one pregnancy was attributed to sperm rebound. This gave a secondary failure rate of 2.3/100 couple years (95% confidence interval of 0.5-4.2/100 couple years). Thus, the total failure rate was 5.2%, and total efficacy was 94.8%. Spermatogenesis in all subjects returned to the normal reference range within the recovery period. The mean serum testosterone concentration increased 131%, and the mean serum LH and FSH concentrations decreased 72% and 70%, respectively, after TU injections during the treatment period. The mean level of serum high density lipoprotein cholesterol decreased (14%), and the mean hematocrit increased 6% compared with baseline. No serious adverse events and no significant changes in serum chemistry occurred during the study. The results showed that monthly TU injection at a dose of 500 mg after an initial loading dose of 1000 mg can effectively, safely, and reversibly suppress spermatogenesis in healthy Chinese men without serious adverse effects.
Author information
Author/s: Gu, Yi-Qun (YQ); Wang, Xing-Hai (XH); Xu, Dwo (D); Peng, Lin (L); Cheng, Li-Fa (LF); Huang, Ming-Kong (MK); Huang, Zhen-Jia (ZJ); Zhang, Gui-Yuan (GY);
Affiliation: National Research Institute for Family Planning, Beijing 100081, China. zgyendan(-atsign-)public.east.net.cn
Journal and publication information
Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
Journal: The Journal of clinical endocrinology and metabolism (J Clin Endocrinol Metab), published in United States. (Language: eng)
Reference: 2003-Feb; vol 88 (issue 2) : pp 562-8
Dates: Created 2003/02/07; Completed 2003/02/28; Revised 2006/11/15;
PMID: 12574181, status: MEDLINE (last retrieved date: 2/18/2009)
Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.
Comments and Corrections
CommentIn: J Clin Endocrinol Metab. 2003 Feb;88(2):559-61. (PMID: 12574180)
External Links for this article
(including full text providers, if available):
Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.
This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.
MeSH headings (categories)
This article was linked to the MeSH Headings (categories) shown below.
Note: Bold headings indicate primary MeSH headings or qualifiers.
Associated Chemicals: Cholesterol, HDL (0) ; Contraceptive Agents, Male (0) ; Hemoglobins (0) ; Testosterone (58-22-0) ; testosterone undecanoate (5949-44-0) ; Luteinizing Hormone (9002-67-9) ; Follicle Stimulating Hormone (9002-68-0)Related articles
These are the most related articles currently in our database:
- An oral regimen of cyproterone acetate and testosterone undecanoate for spermatogenic suppression in men.
30 Oct 1997 - Low dose of cyproterone acetate and testosterone enanthate for contraception in men.
29 Apr 1998 - Stereological evaluation of human spermatogenesis after suppression by testosterone treatment: heterogeneous pattern of spermatogenic impairment. 30 Mar 1998
- Oestradiol enhances testosterone-induced suppression of human spermatogenesis. 28 Feb 2000
- Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone. 29 Nov 2001
- A clinical trial of 7 alpha-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men. 30 Oct 2003
- Depot testosterone with etonogestrel implants result in induction of azoospermia in all men for long-term contraception. 25 Aug 2004
- Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone. 29 Sep 1998
- A novel male contraceptive pill-patch combination: oral desogestrel and transdermal testosterone in the suppression of spermatogenesis in normal men. 30 Oct 2001
Related Article Map
10/30/1997
8/25/2004
Higher Relevance Score (18)
Lower Relevance Score (16)
Legend: - FREE Full text Article. - Abstract only. 
- Title only. More help.
See a larger map of 100+ related articles.